Retatrutide Dosage Calculator: GLP-3 Peptide Dosage Guide & Side Effects

Vendor and community guides describe reconstituting lyophilized (freeze-dried) retatrutide/"GLP-3" powder with bacteriostatic water, injecting it slowly down the inside wall of the vial rather than directly onto the powder to avoid damaging the peptide, and gently swirling (not shaking) until dissolved. Unreconstituted powder is generally recommended to be stored frozen and protected from light; after reconstitution, guides commonly recommend refrigeration at about 2–8°C and use within roughly 2–4 weeks, since the peptide and preservatives can degrade with light exposure, heat, or repeated freeze-thaw cycles.

In clinical trials, retatrutide's side effect profile was similar to other GLP-1-class agonists and was dose-dependent, with gastrointestinal effects (nausea, diarrhea, constipation, vomiting) being the most common, especially during dose increases. Trials also noted a dysesthesia signal — tingling or burning sensations — reported in a meaningful minority of participants at higher doses. Because material sold as "GLP-3" outside clinical channels is unregulated, its actual content, purity, and associated risks are not verified, and reported side effects from non-clinical use should not be treated as an established safety profile.

Because retatrutide/"GLP-3" adds glucagon receptor activation on top of the GLP-1 (and, like tirzepatide, GIP) mechanisms, Phase 2 clinical data reported greater average weight reduction over 48 weeks than has been seen with GLP-1-only drugs like semaglutide or the dual GIP/GLP-1 agonist tirzepatide. Community discussion (largely on peptide- and weight-loss-focused forums) generally echoes this ranking, though real-world results reported informally tend to run below the clinical trial figures. These are research-stage comparisons, not clinical treatment guidance.

Some research and vendor content discusses combining retatrutide/"GLP-3" with other compounds, such as cagrilintide (an amylin analog), on the premise that combining complementary appetite/metabolic pathways could have additive effects. These combinations are discussed in the research and enthusiast community context only; there is no approved combination protocol, and stacking unregulated research chemicals carries additional uncertainty around interactions, dosing, and safety that is not addressed by the available clinical data.